课题基金 / 基金详情

Development of effective targeted anti-GD2 cancer immunotherapies, that synergize with immune-checkpoint inhibitor blockades

Development of effective targeted anti-GD2 cancer immunotherapies, that synergize with immune-checkpoint inhibitor blockades
开发有效的靶向抗 GD2 癌症免疫疗法，与免疫检查点抑制剂阻断协同作用
批准号：
463275
负责人：
Saragovi Horacio U
金额：
$80.81万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2026-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=463275&lang=en
关键词：
Adjuvant Therapy Braf-Pten Mutation Cancer Therapy Combination Therapy Gd2 Immune Checkpoint Inhibition Melanoma Monoclonal Antibody Pd-1 Tumor Ganglioside

项目摘要

项目成果

Saragovi Horacio U的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A tumor marker called GD2 is present almost exclusively on the surface of tumors, such as 80% of human melanoma. GD2 activates pathways that give tumors a growth advantage, and causes immunosuppression giving tumors the ability to evade the immune system,
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovation of Proprietary Liquid Biopsy Assays for Diagnosis of Early Stage Ovarian Cancer
Innovation of a Proprietary Liquid Biopsy Strategy for Diagnosis of Early Stage Ovarian Cancer
Elucidating the paradox of TrkC receptor isoforms causing either neuronal survival or degeneration: target validation and therapeutic rationale using isoform-selective pharmacological and biological tools.
Therapy for motor neuron degeneration diseases targeting the opposing ligand-dependent signals of two TrkC receptor isoforms